Preconditions for warm organ preservation
Post, I.C.J.H.

Citation for published version (APA):

General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: http://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.
Antibiotic prophylaxis in (sub)normothermic organ preservation: \textit{in vitro} efficacy and toxicity of cephalosporins

Ivo C.J.H. Post
Bote G. Bruinsma
Lennart B. van Rijssen
Leonie de Boer
Michal Heger
Sebastian A.J. Zaat
Thomas M. van Gulik

Accepted 2012, Transplantation
Abstract

Bacterial contamination during cold organ preservation occurs without major complications. However, with organ preservation steering towards (sub)normothermic temperatures, bacterial contamination may be detrimental. Since limited evidence exists to support the choice of antibiotic, this study aimed to determine effective antibiotic prophylaxis for (sub)normothermic preservation. Accordingly, we tested whether *S. epidermidis* was capable of growing in a subnormothermic suitable preservation solution (Polysol (PS)) and in solutions designed for cold preservation (University of Wisconsin (UW) solution, histidine-tryptophan-ketoglutarate (HTK) solution, and Belzer-MPS).

Various *S. epidermidis* and *S. aureus* strains were exposed to ceftriaxone and cefazolin concentrations from 0 - 1000 μg/ mL under subnormothermic and normothermic conditions in Polysol. To mimic procedural conditions, the effect of cefazolin was determined after exposure of bacteria to a 20-hour incubation at 28 °C in the presence of cefazolin, and subsequent incubation at 37 °C in the absence of cefazolin. The toxicity of cefazolin was assessed by cell viability and caspase activation assays in porcine kidney endothelial cells. Without antibiotics, Polysol sustained bacterial growth under sub(normothermic) conditions, whereas growth was absent in cold preservation solutions. Cefazolin exhibited a greater bactericidal effect on *S. epidermidis* than ceftriaxone. However, after inoculating PS with 10^6 CFU/ mL, only a cefazolin concentration of 1000 μg/ mL was able to exert a complete bactericidal effect on *S. epidermidis* and *S. aureus* strains and maintain sterility after removal of cefazolin. Finally, 1000 μg/ mL cefazolin showed no adverse effects on porcine kidney endothelial cells.

On the basis of these findings, we recommend that high-dose cefazolin is used for prophylaxis in (sub)normothermic organ preservation with Polysol.
Introduction

A persistent donor organ shortage has stimulated the development of novel, more advanced organ preservation techniques to increase donor organ availability. Expansion of the donor pool by including extended criteria donor organs requires preservation techniques that minimize preservation injury.\(^1\) Hence, organ preservation is steering away from static cold storage, initially to hypothermic (4 °C) machine perfusion preservation, followed by subnormothermic (28 °C) and even normothermic (37 °C) machine perfusion (\((S)\)NMP).\(^2\)

Nutrient-rich preservation solutions and extended preservation times increase the risk of bacterial graft contamination and pose a threat to the graft and the immunocompromised recipient. Graft or preservation solution contamination has a reported clinical incidence of 8 - 62.5 % in transplantations that employ hypothermic preservation, of which up to 17.8 % involves high-risk microorganisms.\(^3-8\) Although graft contamination after hypothermic preservation usually does not result in adverse outcomes, contamination may be detrimental at warmer conditions and in nutrient-rich preservation solutions, as these provide a fecund environment for bacterial growth.\(^4,6\)

An review of recent literature (1990-2012) for studies employing renal or liver (S)NMP revealed that only 14 of 33 recently published papers addressed antibiotic prophylaxis, indicating that antibiotic addition is omitted by many, or grossly underreported.\(^9-13\) Tolboom \textit{et al.}\(^14\), employing a cell culture medium for perfusion, based their choice of penicillin/ streptomycin on successful \textit{in vitro} work (personal communication). High dose cephalosporin (1500 \(\mu\)g/ mL) was used most frequently to prime the perfusion circuit\(^15\) or as a bolus (1000 \(\mu\)g/ mL) per 24 h of perfusion.\(^16\) Cephalosporins are effective against many of the preservation-associated microorganisms in the absence of antibiotic-induced adverse effects.\(^17\)

The use of cephalosporins during (S)NMP has not yet been examined and no guidelines or recommendations for antibiotic prophylaxis during (S)NMP exist. The antibiotic choice must be rationalized by optimal prevention of bacterial growth without causing additional damage to the preserved organ.

This study aimed to establish a suitable antibiotic prophylaxis regime in renal (S)NMP. To this end, \textit{in vitro} models were employed using various \textit{Staphylococcus epidermidis} and \textit{Staphylococcus aureus} strains\(^1\) to determine the bactericidal efficacy. Porcine kidney endothelial cells were used to assess toxicity. The panel of strains also included \textit{Staphylococcus} small colony variants, slow growing variants that form small colonies on
Chapter 6

agar plates which may have a reduced susceptibility to antibiotics and are difficult to diagnose and treat.18

Materials and Methods

Microorganisms and inoculum preparation

*S. epidermidis* strains RP62a (ATCC 35984), O-4719, and the patient-derived strain 6455-I were used. *hemB* mutants of O-47 and 6455-I, O-47mx20 and 6455-II (patient strain), respectively, were included as small colony variants (SCV). Additionally, *S. aureus* strains UAMS-1 (ATCC 49230) and 8325-421 were studied, including the SCV I1022 and the *hemB* mutant of 8325-4.

Inocula were prepared using 50 mL of logarithmic growth phase cultures of the *S. epidermidis* and *S. aureus* strains in tryptic soy broth (TSB, BD Difco, Detroit, MI). The cultures were washed thrice (15,000 xg, 10 min) in 30 mL of the corresponding incubation solution, resuspended, and diluted to 10⁷ colony-forming units (CFU)/mL. Concentrations were determined spectrophotometrically in 1-mL cuvettes at 620 nm (OD₆₂₀nm, Ultraspec 2000, Pharmacia Biotech, Uppsala, Sweden), whereby an OD₆₂₀nm of 0.3 corresponds to 10⁸ CFU/mL.

Culture conditions

Bacterial growth and dose-response experiments were performed in quadruplicate by adding 20 μL of inoculum to 180 μL of the corresponding preservation solution in polypropylene microtiter plates (Greiner Bio-One, Kremsmuenster, Austria). The plates were then incubated while shaking at 80 rpm (Minitron Incubator Shaker, Infors HT, Bottmingen-Basel, Switzerland).

Quantification of bacteria

Bacterial concentration was quantified spectrophotometrically (OD₆₂₀nm) using a filter photometer (AR 2001, Anthos Labtec Instruments, Wals, Austria) and by quantitative culture, i.e., by plating four replicate 10-μL aliquots of 10-fold serial dilutions on blood agar plates (BAP, Columbia agar and 5 % sheep blood, bioMérieux, Marcy l’Etoile, France). The BAP were incubated at 37 °C for 24-48 h, after which CFU were counted (quantitative plating).
Antibiotic prophylaxis in (sub)normothermic organ preservation:

Bacterial growth in preservation solutions

*S. epidermidis* RP62a growth was determined at 37 °C in the experimental, nutrient-rich preservation solution Polysol (PS, Organoflush, Amsterdam, The Netherlands) and compared to growth in TSB over a 24-h period by quantitative plating of samples taken at predefined timepoints.

The growth of the *S. epidermidis* and *S. aureus* strains was monitored by quantitative plating of samples taken at relevant time points during 20 h of shaking incubation at 28 °C in PS and TSB. Subsequently, the temperature was raised to 37 °C and the bacterial concentration was quantified for an additional 48 h. The growth of *S. epidermidis* RP62a was determined in histidine-tryptophan-ketoglutarate solution (HTK, Dr F Köhler-Chemie, Bensheim, Germany), University of Wisconsin solution (UW, Bristol-Myers Squib, New York, NY), Belzer-MPS (Bridge to Life, Colombia, SC), and PS during the same subnormothermic regimen, namely 20 h at 28 °C followed by 48 h at 37 °C.

Efficacy of ceftriaxone and cefazolin

The bacteriostatic effect of ceftriaxone and cefazolin on *S. epidermidis* RP62a in PS was assessed at ceftriaxone (Fresenius Kabi, Bad Homburg, Germany) or cefazolin (Sandoz, Kundl, Austria) concentrations of 0, 75, 150, 300, 600, or 1000 μg/mL, by measuring the OD\(_{620}\) after 0, 2, 4, 6, 8, 12, 24, and 48 h of incubation at 37 °C. In addition, bactericidal activity was determined by quantitative culture.

Dose-response of cefazolin under (sub)normothermic conditions

Cefazolin’s bactericidal capacity against the *S. epidermidis* and *S. aureus* strains was assessed during *in vitro* (sub)normothermic incubation in PS. To this end, 0, 300, or 1000 μg/mL cefazolin was added to microtiter plates, prepared as described above. Plates were incubated for 68 h at 37 °C or 20 h at 28 °C, followed by 48 h at 37 °C. CFU/mL were determined by quantitative culture of the samples.

Washout of cefazolin during organ reperfusion was simulated *in vitro* to assess its effect on residual bacterial growth. Cefazolin was added at a concentration of 0, 300, and 1000 μg/mL to 5 mL of *S. epidermidis* RP62a-inoculated PS. After 20 h of incubation at 28 °C (shaking), the cefazolin was removed by washing the bacteria three times in 5 mL PS (15,000 ×g, 10 min, 20 °C) and resuspending the pelleted bacteria in an equal volume of PS as used for the first incubation period. These suspensions were subsequently incubated for another 24 h at 37 °C. Bacterial growth was determined by quantitative culture and compared to suspensions in which cefazolin had not been washed out.
Isolation of porcine kidney endothelial cells

Mature porcine kidney endothelial cells (PKEC) were isolated from kidneys of 30-kg male Landrace pigs (van BeekTopigs BV, Lelystad, The Netherlands). After 5 min of warm ischemia following a cardiac resection, the endothelial cells were procured from the kidneys. Kidneys were flushed using HTK and phosphate buffered saline (PBS, Fresenius Kabi) followed by infusion of 10 mL of 0.04 % Liberase (Roche, Basel, Switzerland) in PBS through the renal artery. The kidney was incubated for 26 min at 37 °C and flushed with 20 % fetal calf serum (FCS; Lonza, Verviers, Belgium)-enriched endothelial cell growth medium (ECGM, Promocel, Heidelberg, Germany) to obtain detached endothelial cells. The PKEC were subsequently cultured to confluence at 37 °C in culture flasks (T25 Primaria, BD Biosciences, Franklin Lakes, NJ) in a humidified 5 % CO₂ atmosphere.

After reaching confluence, cells were collected after brief treatment with 1 mL of Accutase (Innovative Cell Technologies, San Diego, CA), washed in PBS (400 ×g, 10 min, 4 °C), and resuspended in Williams medium E (WE, Lonza) containing 20 % FCS. Next, an equal volume of WE containing 20 % fresh DMSO was slowly added to the cell suspensions up to a final volume of 1.8 mL, after which the cell suspensions were stored in liquid nitrogen.

Prior to use, cells were thawed and washed twice with 18 mL of 20 % FCS-enriched WE (400 ×g, 10 min, 4 °C). The cell pellet was resuspended in 5 mL ECGM and cultured as described. Cells were used after the third passage had become confluent.

Cell viability and caspase induction

PKEC were seeded in fibronectin (Sigma-Aldrich, St. Louis, MO)-coated 24-wells culture plates (Corning Incorporated, Corning, NY) and cultured in ECGM. Upon reaching confluence, cell viability and caspase 3 and 7 levels were determined after 0 h and 8 h.

Cell viability was determined with a tetrazolium salt assay (WST-1, Roche). The medium was aspirated, the wells incubated in WST reagent (300 µL per well) and incubated for 30 min at 37 °C. The absorbance was measured using a Synergy HT microplate reader (λₘₐₓ = 440 nm, BioTek, Winooski, VT).

Caspase 3 and 7 levels were determined using a fluorochrome inhibitor of caspase (FLICA) kit (reference# A20173, AbD Serotec, Oxford, UK) according to the manufacturer’s instructions (λₘₐₓ = 575 nm, λₑₘ = 620 nm).

WST and caspase data were normalized to protein content (Bradford protein assay, BioRad, Hercules, CA) and expressed as a percentage of the mean of the 0-h values.
Statistical analysis

Statistical analysis of differences in bacterial concentrations was performed using a 2-way analysis of variance (ANOVA) with a Bonferroni post-hoc test between groups, and unpaired-sample Student’s t-test between time points within one group. Toxicity data were analyzed using a Kruskal-Wallis test with Dunn’s multiple comparison test (α = 0.05). A P-value of <0.05 was considered statistically significant.

Results

Bacterial growth in preservation solutions

Significant *S. epidermidis* RP62a growth was observed in both TSB and PS. However, a ten-fold larger increase in CFU/mL was observed in TSB after 24 h (P < 0.001, Figure 1). After 20 h of incubation at 28 °C and subsequently for 48 h at 37 °C, growth of all *S. epidermidis* and *S. aureus* strains occurred in both TSB (Figure 2A) and PS (Figure 2B). In PS, however, the numbers of CFU of *S. aureus* 8325-4 and its SCV strain I10 decreased until 44 h, but increased to numbers similar to those of the other strains at 68 h. No differences in growth in TSB and PS were observed between the wild type and corresponding SCV strains. In general, the strains grew to higher numbers of CFU in TSB than in PS. While there was growth of *S. epidermidis* RP62a in TSB and PS, the numbers of CFU decreased during the total 68-h incubation in HTK, UW solution, or Belzer-MPS (Figure 2C).

Figure 1.
Growth kinetics of *S. epidermidis* RP62a in Polysol (PS) and tryptic soy broth (TSB) during 24 h at 37 °C. * indicates a significant difference from TSB.
Figure 2.
Growth kinetics of *S. epidermidis* and *S. aureus* strains in Polysol (PS) (A) and in tryptic soy broth (TSB) (B) during incubation at 28 °C for 20 h followed by 48 h at 37 °C. C) Growth curve of *S. epidermidis* RP62a in different preservation solutions and TSB. Belzer MPS: Machine Perfusion Solution-Belzer; UW: University of Wisconsin solution; HTK: histidine-tryptophan-ketoglutarate solution.

* indicates a significant difference in bacterial concentration between PS and Belzer-MPS, UW, and HTK. See Appendix 1, page 207 for the color image.
Antibiotic prophylaxis in (sub)normothermic organ preservation:

Figure 3.
Bactericidal effect of ceftriaxone and cefazolin on *S. epidermidis* RP62a.
The dose-response curves after A) 2 h and B) 12 h incubation at 37 °C show the bactericidal efficacy in TSB (dashed lines) and in PS (solid lines).

**Efficacy of cefazolin and ceftriaxone**

In the absence of antibiotics, *S. epidermidis* RP62a showed significant growth during the first 12 h (*P*<0.001). A slightly increased OD$_{620\text{nm}}$ was observed after 48-h incubation in TSB with 75 μg/ mL ceftriaxone (NS). In all other incubations the antibiotic inhibited the growth of the bacteria. Based on spectrophotometric measurements, cefazolin had superior bactericidal efficacy over ceftriaxone, which was confirmed by quantitative plating (Figure 3A/ B). After 2 and 12 h, 75 μg/ mL of cefazolin was sufficient to reduce the numbers of CFU/ mL of *S. epidermidis* RP62a below the detection limit. In contrast, ceftriaxone required a concentration of 1000 and 300 μg/mL after 2 and 12 h, respectively, to obtain a similar bactericidal effect.
Figure 5.
Efficacy of cefazolin against *S. epidermidis* and *S. aureus* strains cultured at 28 °C for 20 h, followed by 48 h at 37 °C. Each graph shows the concentration of the respective bacterial strains and the three lines indicate different concentrations of cefazolin.
Figure 4.
Efficacy of cefazolin on *S. epidermidis* and *S. aureus* strains under normothermic conditions. Each graph shows the concentration of the respective bacterial strains, and the three lines indicate different concentrations of cefazolin.
Figure 6.
Effect of the removal of cefazolin on continued growth of *S. epidermidis* RP62a.

*S. epidermidis* RP62a were exposed to the indicated cefazolin concentrations for 20 h at 28 °C, after an temperature increase to 37 °C without any changes in the solution (solid lines), or after replacement of the cefazolin-containing solution with antibiotic-free solution.

Dose-response of cefazolin under (sub)normothermic conditions

Incubation of *S. epidermidis* and *S. aureus* strains at 37 °C in PS with cefazolin led to a complete elimination of most strains (Figure 4). A 1000-μg/mL concentration decreased the bacterial concentration to below the detection limit at t=44 h, while 300 μg/mL led to a slower elimination and was insufficient to eradicate the SCV *S. epidermidis* strain 6455-I. To mimic subnormothermic preservation and normothermic post-transplantation conditions, *S. epidermidis* was incubated in PS for 20 h at 28 °C and subsequently for 24 h at 37 °C. The bactericidal effect was less prominent at 28 °C compared to 37 °C, but subsequent warming to 37 °C greatly enhanced the effect (Figure 5). Again, a concentration of 1000 μg/mL was able to consistently reduce bacterial numbers to undetectable values by t=44 h, while 300 μg/mL led to slower and incomplete eradication.

Removal of the cefazolin prior to warming from 28 °C to 37 °C allowed *S. epidermidis* RP62a growth in the suspensions to which 300 μg/mL had initially been added (Figure 6). However, an increase in CFU/mL was deterred up to 12 h compared to the antibiotic-free control. Only an initial cefazolin concentration of 1000 μg/mL was
capable of reducing bacterial CFU in PS to below the limit of detection after cefazolin had been removed.

Figure 7.
Caspase 3 and 7 levels (red bars) and metabolic capacity (WST, white bars) after 8 h exposure to various cefazolin concentrations are shown as the percentage change versus t= 0 h. WST: water soluble tetrazolium; FLICA: fluorochrome inhibitor of caspase.
* indicates a significant decrease in caspase 3 and 7 levels from t= 0 h compared to 0 μg/mL.

Cytotoxicity of cefazolin to porcine kidney endothelial cells
After 8-h incubation, the change in PKEC viability relative to t = 0 h did not differ significantly between the 0 μg/ mL and the 1000 μg/ mL cefazolin concentrations (21.1 % and 26.5 % increase) and all other concentrations (Figure 7). Furthermore, caspases 3 and 7 activation remained absent regardless of the cefazolin concentration. Interestingly, incubation in 300 μg/ mL cefazolin was associated with a reduced extent of apoptosis compared to control (0 μg/ mL) after 8 h (-24.8 % and -4.3 %, respectively, P <0.05). Accordingly, no evidence of cytotoxicity of high-dose cefazolin was observed in PKEC.
Discussion

This is the first study to describe the growth of *S. epidermidis* and *S. aureus* wild type and SCV strains in different preservation media during (sub)normothermic conditions, and their susceptibility to antibiotic prophylaxis. The main findings were: 1) bacterial growth in (S)NMP preservation solutions is a risk at (sub)normothermic conditions, 2) in the nutrient-rich PS, the bactericidal efficacy of cefazolin is greater than that of ceftriaxone, 3) 1000 μg/mL of cefazolin is bactericidal during subnormothermic and at normothermic incubation, even after cefazolin removal, and 4) 1000 μg/mL cefazolin is non-toxic to PKEC *in vitro*.

High rates of bacterial contamination in organ preservation solutions have always been a reason for concern. While hypothermia appears to prevent bacterial growth and limit infectious complications, bacteria remain viable after hypothermic preservation, even in the presence of penicillin and trimethoprim/sulfamethoxazole. With the current preservation techniques moving from static hypothermic storage to dynamic (sub)normothermic techniques, more aggressive antimicrobial prophylaxis is required to ensure sterility of nutrient-rich preservation solutions and the *ex vivo* preserved organ. We found that HTK and UW did not support bacterial growth under (sub)normothermic conditions, which is likely due to the absence of nutritional constituents for bacteria in these solutions. PS, developed primarily for warm preservation, did facilitate significant bacterial growth, implying that a potential risk for other novel, (S)NMP preservation solutions exists as well.

New insights into the nature of the microorganisms responsible for significant infections should be taken into account when determining appropriate prophylaxis. In this respect, SCV are associated with a slow growth rate, atypical colony morphology, and aberrant biochemical properties that are thought to make them less susceptible to many antibiotics and therefore, responsible for persistent and latent infections. *S. aureus* 8325-4 and its SCV have been shown to be equally infective and comparably susceptible to cephapirin. Accordingly, our findings show similar efficacy of cefazolin across different strains and their respective SCV, supporting the broad antimicrobial coverage of cefazolin. Furthermore, the continuing bactericidal effect after removal of the antibiotic appears to be instrumental in preventing latent infections.

The *in vitro* model presented here allowed sensitive and controlled determination of bacterial growth and antibiotic susceptibility. However, this model is not a perfect representation of the complex interaction between preservation solution and the various compartments of the organ. In previously performed, contaminated, isolated
Antibiotic prophylaxis in (sub)normothermic organ preservation: ex vivo renal perfusion experiments using PS at subnormothermic conditions, peritubular capillary obstruction occurred due to bacterial overgrowth, compromising perfusion (data not shown). By showing effective prophylaxis of cefazolin against high concentrations of frequent bacterial contaminants, a solid basis is provided for the use of this antibiotic in (S)NMP systems.

Prophylactic addition of antimicrobial agents to preservation solutions has been common practice for decades. However, current experimental and clinical preservation protocols frequently neglect antibiotic prophylaxis, and, where reported, do not address sterility and antibiotic toxicity, despite high contamination rates and nephrotoxicity, respectively. It is likely that this stems from the absence of an evidence-based recommendation. Our results provide compelling in vitro rationalization for the use of high-dose cefazolin, which is efficacious against the major contaminating staphylococcal species and even against their SCV. When combined with bacterial culturing according to standard operating procedures, high dose cefazolin could help minimize infectious complication following (S)NMP.

In conclusion, a 1000 μg/ mL cefazolin dose is effective against multiple S. epidermidis and S. aureus strains and their SCV at 28 °C and 37 °C in PS, and was non-toxic for PKEC. It is therefore recommended to use high-dose cefazolin as antibiotic prophylaxis during warm kidney preservation with Polysol.
References


Antibiotic prophylaxis in (sub)nornormoergic organ preservation:


